Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 5.3% – Time to Sell?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF)’s share price was down 5.3% on Wednesday . The stock traded as low as $8.85 and last traded at $8.85. Approximately 456 shares were traded during trading, a decline of 88% from the average daily volume of 3,765 shares. The stock had previously closed at $9.35.

Telix Pharmaceuticals Stock Down 5.3%

The stock’s fifty day moving average price is $7.53 and its 200-day moving average price is $8.59.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.